Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

針對症狀 HER2-positive Breast Cancer
臨床試驗編號 NCT00791037
臨床階段 Phase I/II
臨床試驗位址 Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
目前研究進度 This study is currently recruiting participants.
試驗開始日期 November 13, 2008
試驗開始日期 October 26, 2012
臨床目的 This phase I/II trial is studying the side effects and best dose of adoptive T cell therapy in treating patients with stage IV breast cancer. Vaccines are given to patient prior the expansion of a person's white blood cells may help the body build an effective immune response to kill tumor cells that overexpress human epidermal growth factor receptor 2 (HER2)
This phase I/II trial is studying the side effects and best dose of adoptive T cell therapy in treating patients with stage IV breast cancer. Vaccines are given to patient prior the expansion of a per